KRAS and gastric neoplasm: Our data indicate that gastric tumor-associated cells shed from the primary tumor together with accompanying cancer cells survive to a secondary site and proliferate within the metastatic nodules in the lung in the absence of anti-Kras nanobeacons treatment.